Special Issue on “Oxidative stress as therapeutic target:
Pharmaceutical and pharmacological aspects”
Call For Papers

Guest Editors

Prof. Luciano Saso
Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Italy
Website: https://www.researchgate.net/profile/Luciano_Saso
E-mail [email protected]

 

Prof. Sibel Süzen
Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara University, Turkey
Website: https://www.researchgate.net/profile/Sibel_Suzen
E-mail: [email protected]

 

Prof. Özge Ulker
Faculty of Pharmacy, Department of Toxicology, Ankara University, Turkey
Website: https://www.researchgate.net/profile/Ozge_Ulker
E-mail: [email protected]

 

 

Oxidative stress (OS) is involved in the pathogenesis of several diseases including cancer, neurodegenerative diseases, cardiovascular diseases, lung diseases, kidney fibrosis, metabolic syndrome, diabetes, etc. even if often it is not clear whether it is one of the causes or just a consequence of the pathological condition.

Unfortunately, most of the clinical trials of antioxidants failed in the last few years for different reasons reviewed elsewhere (1) but some antioxidant therapies have been shown to be effective (2). Besides, in neoplastic diseases pro-oxidant therapies rather than antioxidants can be beneficial. Thus, referring to redox therapies, the expression “modulators of oxidative stress” appears more appropriate than just “antioxidants”.

Furthermore, in the past few years, it has become clear that in most cases antioxidants do not act in vivo as radical scavengers as they do in vitro but rather on signaling pathways such as the Nrf2/Keap1/ARE (3-5).

The main aim of this Special Issue is to collect papers on pharmaceutical and pharmacological aspects of the development of therapeutic strategies for modulation of OS. Both research articles and reviews can be submitted. Potential topics include, but are not limited to:

  • etiopathogenetic mechanisms involving OS
  • non-radical scavenging mechanisms of action of OS modulators
  • the Nrf2/Keap1/ARE and other signaling pathways related to OS
  • future development of Nrf2-targeted therapeutics
  • cytokines and OS in inflammatory diseases
  • in vitro and in vivo studies of OS modulators;
  • development of antioxidant and pro-oxidant drugs
  • epidemiological and clinical studies on the efficacy of redox therapies
  • relevant biomarkers for assessing in vivo antioxidant and pro-oxidant activity.

 

DEADLINE FOR SUBMISSIONS: 30th November 2020

 

Please submit to https://mc.manuscriptcentral.com/jppharm. Please indicate on submission that your article is to be considered for the OXIDATIVE STRESS AS THERAPEUTIC TARGET: PHARMACEUTICAL AND PHARMACOLOGICAL ASPECTS special issue.

 

 

Selected references

  1. Firuzi, O., Miri, R., Tavakkoli, M., Saso, L. (2011). Antioxidant therapy: current status and future prospects. Chem. 18, 3871–3888.
  2. Saso, L.,Firuzi, O. (2014). Pharmacological applications of antioxidants: lights and shadows. Drug Targets, 15, 1177–1199.
  3. Telkoparan-Akillilar, P., Suzen, S., Saso, L. (2019). Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic J. Mol. Sci. 20, 2025.
  4. Panieri, E., Saso, L. (2019). Potential Applications of NRF2 Inhibitors in Cancer Therapy. Cell. Longev. 8592348.
  5. Sova, M., Saso, L. (2018). Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review. Drug Des. Devel Ther. 12, 3181–3197.